Effect of Ranolazine on control of Diabetes Mellitus

Randomized placebo controlled study of the effect of Ranolazine on HbA1c level in Type 2 diabetes mellitus

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2014/12/005265

Enrollment

Registered

2014-12-08

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Type 2 Diabetes Mellitus

Interventions

Intervention1: TABLET RANOLAZINE: Ranolazine 500 mg BID Orally for 12 weeks Control Intervention1: Dummy medication with vitamin c tablets: 500 mg BID orally for 12 weeks

Eligibility

Inclusion criteria

Inclusion criteria: • 18 to65 years old • Subjects with T2DM currently on non-insulin antidiabetic therapy (metformin) in addition to diet and exercise • Body mass index (BMI) >= 20 kg/m2 and • HbA1c 7 - 10% • Female of child-bearing potential must agree to use effective methods of contraception • Signed written informed consent

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Change from baseline in HbA1c at Week 12 Change from baseline in 2-hour postprandial serum glucose at Week 12 Change from baseline in fasting serum glucose at Week 12 Timepoint: 12 weeks	—

Secondary

Measure	Time frame
Change from baseline in fasting serum C-peptide at Weeks 12 Change from baseline in fasting serum insulin at Weeks 12 Timepoint: 12 WEEKS	—

Countries

India

Contacts

Public ContactSomnath Maity

IPGMER, Department of Pharmacology

profamkd@gmail.com9831728494

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026